Patent details
301226
Product Name:
Midazolam HCI, in de vorm van een ethanol/propyleenglycol solubilisaat
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301226
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1703896
Status:
Application Pending
Application number:
301226
Procedural language:
Dutch
First Applicant Residence Country:
Belgium (BE)
Marketing Authorization
1
Marketing Authorization Number:
RVG126266; RVG126267; RVG126268
Marketing Authorization Type:
National/EU
Marketing Authorization Date:
13/10/2022
Marketing Authorization Country:
Netherlands (NL)
2
Marketing Authorization Number:
MTnr 20-13328; MTnr. 20-13329; Mtnr. 20-13330
Marketing Authorization Type:
EEA
Marketing Authorization Date:
22/09/2022
Marketing Authorization Country:
Norway (NO)
Dates
Filing date:
12/04/2023
First Marketing Authorization date:
22/09/2022
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
13/04/2023
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
12/04/2023
Name:
F.W.H.M. Merkus
Address:
Grootreesdijk 26, 2460, Kasterlee, Belgium (BE)
Agent
Name:
dr. R.C. van Duijvenbode c.s.
From:
12/04/2023
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
Bulletin Heading:
SPC
Journal edition number:
16/23
Publication date:
19/04/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
13/04/2023
Outgoing Correspondence
Confirmation receipt request
1
PDF
/2/3/9/7/6/0800867932/docs/301226_7_541162l174.pdf
12/04/2023
Application Form
First filed application form
2
PDF
/2/3/9/7/6/0800867932/docs/301226_0_applicationform20230413032005191.pdf
12/04/2023
SPC Documents
Summary of the characteristics of the product
19
PDF
/2/3/9/7/6/0800867932/docs/301226_1_supplprotectioncertificate20230413032251068.pdf
12/04/2023
SPC Documents
Marketing Authorization SPC
1
PDF
/2/3/9/7/6/0800867932/docs/301226_2_supplprotectioncertificate20230413032135796.pdf
12/04/2023
SPC Documents
Marketing Authorization SPC
1
PDF
/2/3/9/7/6/0800867932/docs/301226_3_supplprotectioncertificate20230413032340772.pdf
12/04/2023
SPC Documents
Marketing Authorization SPC
1
PDF
/2/3/9/7/6/0800867932/docs/301226_4_supplprotectioncertificate20230413032201411.pdf
12/04/2023
SPC Documents
Marketing Authorization SPC
2
PDF
/2/3/9/7/6/0800867932/docs/301226_5_supplprotectioncertificate20230413032316796.pdf
12/04/2023
SPC Documents
Accompanying letter SPC
1
PDF
/2/3/9/7/6/0800867932/docs/301226_6_supplprotectioncertificate20230413032413840.pdf